Avastin (Renal Cell Carcinoma) - Analysis and Forecasts to 2022

Transcription

1 Brochure More information from Avastin (Renal Cell Carcinoma) - Analysis and Forecasts to 2022 Description: Avastin (Renal Cell Carcinoma) Analysis and Forecasts to 2022 Summary Our pharmaceuticals report, Avastin (Renal Cell Carcinoma) Analysis and Forecasts to 2022 provides Avastin sales forecasts for US and EU5. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period ( ). The report also includes information on Renal Cell Carcinoma market. This report is built using data and information sourced from Our proprietary databases, primary and secondary research using Company s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by Our team of industry experts. Scope - Therapy area profile including patient population for the US and EU5 - Analysis and review of Avastin including sales data - Qualitative and quantitative assessment of market space - Analysis of the trends, drivers and restraints shaping and defining the markets - In-depth analysis of Avastin including efficacy, safety, pricing, competition and other details which influence its sales potential - Detailed sales forecast for for Avastin in the US and EU5 Reasons to buy - Understand and capitalize by identifying products that are most likely to ensure a robust return - Stay ahead of competition by understanding the changing competitive landscape - Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential - Make more informed business decisions from insightful and in-depth analysis of the drug s performance - Examine the historical sales performance of a drug in seven major markets - Obtain sales forecast for currently marketed/pipeline drug for for all seven major markets Keywords Avastin, Renal Cell Carcinoma,Ovarian cancer, colorectal cancer, breast cancer, non-small cell lung cancer, gioblastoma Genentech Inc., anti vascular endothelial growth factor, interferon alfa, monoclonal antibody, Competitors to Avastin, sales forecast Contents: List of Tables 1.2 List of Figures 2 Introduction 2.1 RCC Types of Renal Cell Carcinoma 2.2 RCC Market 2.3 Epidemiology 2.4 Pathophysiology 2.5 Etiology Cigarette Smoking Obesity Acquired Cystic Disease Hypertension

2 2.5.5 Family History of Kidney Cancer High Blood Pressure Usage of Certain Medicines Advanced Kidney Disease Gender and Race Genetic and Hereditary Risk Factors Symptoms Diagnosis 2.6 GlobalData Pipeline Report Guidance 3 RCC Disease: Market Characterization 3.1 RCC Disease Market 3.2 RCC Disease Market Forecasts and CAGR 3.3 Drivers for the RCC Disease Market High Incidence High Prevalence Emergence of Targeted Therapies Large Unmet Need 3.4 Tumor-Node-Metastases (TNM) Classification of RCC Staging Grading Prognosis 3.5 Treatment Options in RCC Surgery Radiation therapy Chemotherapy Targeted Therapies Tyrosine Kinase Inhibitors Mammalian Target of Rapamycin (mtor) Inhibitor Vascular Endothelial Growth Factor (VEGF) Inhibitor Treatment by Stage 3.6 Classification of Patients with RCC 4 Avastin (bevacizumab) 4.1 Introduction 4.2 Mechanism of Action 4.3 Clinical Studies 4.4 Approval History of Avastin 4.5 Factors Affecting Sales of Avastin High Efficacy Rejection in the UK Lack of Approval in Japan Increasing Competition 4.6 Drug Evaluation Drug Risk Benefit Score Intensity of Competition 4.7 Sales Forecasts Target Patient Pool of Avastin Dosing Market Penetration Annual Cost of Therapy Sales Projections of Avastin 5 RCC Market: Appendix 5.1 Market Definitions 5.2 Abberiviations 5.3 Research Methodology Coverage Secondary Research Forecasting Number of Patients Approved to Take the Drug Net Penetration of Drug Net Annual Dosing Annual Cost of Therapy 5.4 Drug Sales Estimates Model 5.5 Contact Us

3 5.6 Disclaimer 5.7 Sources 1.1 List of Tables Table 1: RCC, Incidences and Mortality, Table 2: RCC, TNM Classification Table 3: RCC, Fuhrman grading system Table 4: RCC, Treatment Guidelines Table 5: Avastin, Renal Cell Carcinoma, Phase III Clinical Study Results Table 6: Approval History of Avastin Table 7: Avastin, Renal Cell Carcinoma, Drug Risk Benefit Score Table 8: Avastin, Renal Cell Carcinoma, Global, Annual Cost of Therapy ($), 2011 Table 9: Avastin, Renal Cell Carcinoma, Global, Sales Estimates ($m), Table 10: Avastin, Renal Cell Carcinoma, The US, Sales Estimates ($m), Table 11: Avastin, Renal Cell Carcinoma, The UK, Sales Estimates ($m), Table 12: Avastin, Renal Cell Carcinoma, France, Sales Estimates ($m), Table 13: Avastin, Renal Cell Carcinoma, Germany, Sales Estimates ($m), Table 14: Avastin, Renal Cell Carcinoma, Italy, Sales Estimates ($m), Table 15: Avastin, Renal Cell Carcinoma, Spain, Sales Estimates ($m), List of Figures Figure 1: Worldwide Incidence and Mortality Distribution of Top 20 Cancers (%), 2010 Figure 2: Total number of cigarettes consumed, The US, Figure 3: RCC, Global, Market Size Forecasts ($bn), Figure 4: RCC, Global, Incidence (in million), Figure 5: Oncology, Worldwide, Incidence (in million), Figure 6: RCC, TNM Staging System Figure 7: RCC, Marketed drug targets Figure 8: RCC, Surgical Management Figure 9: Treatment Algorithm for Metastatic Renal Cell Carcinoma Figure 10: Classification of Patients with RCC Figure 11: Renal Cell Carcinoma, Avastin, Drug Model Diagram Figure 12: Avastin, Renal Cell Carcinoma, Global, Sales Estimates ($m), Figure 13: Avastin, Renal Cell Carcinoma, The US, Sales Estimates ($m), Figure 14: Avastin, Renal Cell Carcinoma, The UK, Sales Estimates ($m), Figure 15: Avastin, Renal Cell Carcinoma, France, Sales Estimates ($m), Figure 16: Avastin, Renal Cell Carcinoma, Germany, Sales Estimates ($m), Figure 17: Avastin, Renal Cell Carcinoma, Italy, Sales Estimates ($m), Figure 18: Avastin, Renal Cell Carcinoma, Spain, Sales Estimates ($m), Figure 19: Avastin, Renal Cell Carcinoma, Global, Sales Distribution by Country (%), 2018 Figure 20: Patients Approved for the Drug Ordering: Order Online - Order by Fax - using the form below Order by Post - print the order form below and send to Research and Markets, Guinness Centre, Taylors Lane, Dublin 8,

4 Page 1 of 2 Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to (from USA) or (from Rest of World). If you have any questions please visit Order Information Please verify that the product information is correct and select the format(s) you require. Product Name: Avastin (Renal Cell Carcinoma) - Analysis and Forecasts to 2022 Web Address: Office Code: Product Formats Please select the product formats and quantity you require: SC Single User: Site License: Enterprisewide: Quantity USD 2000 USD 4000 USD 6000 Contact Information Please enter all the information below in BLOCK CAPITALS Title: Mr Mrs Dr Miss Ms Prof First Name: Last Name: Address: * Job Title: Organisation: Address: City: Postal / Zip Code: Country: Phone Number: Fax Number: * Please refrain from using free accounts when ordering (e.g. Yahoo, Hotmail, AOL)

5 Page 2 of 2 Payment Information Please indicate the payment method you would like to use by selecting the appropriate box. Pay by credit card: You will receive an with a link to a secure webpage to enter your credit card details. Pay by check: Please post the check, accompanied by this form, to: Research and Markets, Guinness Center, Taylors Lane, Dublin 8, Pay by wire transfer: Please transfer funds to: Account number Sort code Swift code IBAN number Bank Address ULSBIE2D IE78ULSB Ulster Bank, Main Street, Blackrock, Co. Dublin, If you have a Marketing Code please enter it below: Marketing Code: Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at Please fax this form to: (646) or (646) From USA or From Rest of World